JP2022500500A5 - - Google Patents
Info
- Publication number
- JP2022500500A5 JP2022500500A5 JP2021538171A JP2021538171A JP2022500500A5 JP 2022500500 A5 JP2022500500 A5 JP 2022500500A5 JP 2021538171 A JP2021538171 A JP 2021538171A JP 2021538171 A JP2021538171 A JP 2021538171A JP 2022500500 A5 JP2022500500 A5 JP 2022500500A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024106451A JP2024114982A (ja) | 2018-09-10 | 2024-07-01 | カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729010P | 2018-09-10 | 2018-09-10 | |
| US62/729,010 | 2018-09-10 | ||
| PCT/US2019/050349 WO2020055824A1 (en) | 2018-09-10 | 2019-09-10 | Dry powder formulation of caveolin-1 peptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024106451A Division JP2024114982A (ja) | 2018-09-10 | 2024-07-01 | カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500500A JP2022500500A (ja) | 2022-01-04 |
| JP2022500500A5 true JP2022500500A5 (https=) | 2022-09-09 |
| JPWO2020055824A5 JPWO2020055824A5 (https=) | 2022-09-09 |
| JP7514840B2 JP7514840B2 (ja) | 2024-07-11 |
Family
ID=69778150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538171A Active JP7514840B2 (ja) | 2018-09-10 | 2019-09-10 | カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 |
| JP2024106451A Pending JP2024114982A (ja) | 2018-09-10 | 2024-07-01 | カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024106451A Pending JP2024114982A (ja) | 2018-09-10 | 2024-07-01 | カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US12280088B2 (https=) |
| EP (1) | EP3849581A4 (https=) |
| JP (2) | JP7514840B2 (https=) |
| KR (1) | KR20210057127A (https=) |
| CN (2) | CN112996530B (https=) |
| AU (1) | AU2019339264B2 (https=) |
| BR (1) | BR112021004420A2 (https=) |
| CA (1) | CA3109982A1 (https=) |
| WO (1) | WO2020055824A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110201144B (zh) | 2013-03-15 | 2024-01-02 | 得克萨斯州大学系统董事会 | 用Nutlin-3a和肽抑制肺纤维化 |
| WO2016138413A1 (en) * | 2015-02-27 | 2016-09-01 | Board Of Regents, The University Of Texas System | Polypeptide therapeutics and uses thereof |
| AU2019339260B2 (en) | 2018-09-10 | 2025-06-26 | Rein Therapeutics, Inc. | Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis |
| US20240082342A1 (en) * | 2018-11-21 | 2024-03-14 | Board Of Regents, The University Of Texas System | Peptide therapeutics for increasing lung cell viability |
| US20220370544A1 (en) * | 2018-11-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Peptide therapeutics for acute and chronic airway and alveolar diseases |
| WO2020185826A1 (en) * | 2019-03-11 | 2020-09-17 | Lung Therapeutics, Inc. | Compositions and methods for protecting type 2 alveolar epithelial cells (aec2) |
| EP4138791A1 (en) * | 2020-04-20 | 2023-03-01 | Board of Regents, The University of Texas System | Biologically active dry powder compositions and method of their manufacture and use |
| US20230159608A1 (en) * | 2020-04-21 | 2023-05-25 | Lung Therapeutics, Inc. | Modified peptide fragments of cav-1 protein and uses thereof |
| US20230226149A1 (en) * | 2020-06-19 | 2023-07-20 | Lung Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury |
| US20250041383A1 (en) * | 2021-06-17 | 2025-02-06 | Lung Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of post-acute covid-19 |
| US20250262273A1 (en) * | 2021-10-22 | 2025-08-21 | Rein Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of chronic kidney disease |
| EP4719450A2 (en) * | 2023-05-30 | 2026-04-08 | Rein Therapeutics, Inc. | Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof |
| CN121695995A (zh) * | 2024-09-18 | 2026-03-20 | 深圳翰宇药业股份有限公司 | 一种多肽药物的粉碎方法 |
| CN119661656A (zh) * | 2024-11-20 | 2025-03-21 | 华中科技大学同济医学院附属梨园医院 | 一种靶向拮抗pCAV1的多肽及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| IT1190891B (it) | 1982-06-24 | 1988-02-24 | Anic Spa | Metodo per la sintesi in fase solida di polipeptidi retroinvertiti |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| CN1091138A (zh) | 1992-08-27 | 1994-08-24 | 迪金研究有限公司 | 疫苗 |
| US20020077283A1 (en) * | 2000-09-08 | 2002-06-20 | Sessa William C. | Caveolin peptides and their use as therapeutics |
| GB0119852D0 (en) | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
| EP1501479A1 (en) | 2002-05-07 | 2005-02-02 | Nektar Therapeutics | Capsules for dry powder inhalers and methods of making and using same |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| US7625865B2 (en) | 2004-03-26 | 2009-12-01 | Universita Degli Studi Di Parma | Insulin highly respirable microparticles |
| EP2074142A4 (en) * | 2006-10-19 | 2010-10-27 | Angiochem Inc | COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF |
| EP2635686B1 (en) | 2010-11-05 | 2018-03-28 | The Regents of The University of California | Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord |
| BR112015022831A2 (pt) | 2013-03-13 | 2017-08-22 | Forest Laboratories Holdings Ltd | Composições farmacêuticas micronizadas |
| CN110201144B (zh) * | 2013-03-15 | 2024-01-02 | 得克萨斯州大学系统董事会 | 用Nutlin-3a和肽抑制肺纤维化 |
| WO2015080980A2 (en) | 2013-11-26 | 2015-06-04 | E&B Technologies Llc | Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators |
| EP3262856B1 (en) * | 2015-02-27 | 2020-02-19 | PCMS Holdings, Inc. | Systems and methods for secure roll-over of device ownership |
| WO2016138413A1 (en) * | 2015-02-27 | 2016-09-01 | Board Of Regents, The University Of Texas System | Polypeptide therapeutics and uses thereof |
-
2019
- 2019-09-10 KR KR1020217010694A patent/KR20210057127A/ko not_active Ceased
- 2019-09-10 WO PCT/US2019/050349 patent/WO2020055824A1/en not_active Ceased
- 2019-09-10 CN CN201980073144.0A patent/CN112996530B/zh active Active
- 2019-09-10 JP JP2021538171A patent/JP7514840B2/ja active Active
- 2019-09-10 AU AU2019339264A patent/AU2019339264B2/en active Active
- 2019-09-10 CA CA3109982A patent/CA3109982A1/en active Pending
- 2019-09-10 US US17/274,666 patent/US12280088B2/en active Active
- 2019-09-10 CN CN202510651536.8A patent/CN120459067A/zh active Pending
- 2019-09-10 BR BR112021004420-5A patent/BR112021004420A2/pt unknown
- 2019-09-10 EP EP19859836.9A patent/EP3849581A4/en active Pending
-
2024
- 2024-02-06 US US18/434,731 patent/US12280089B2/en active Active
- 2024-07-01 JP JP2024106451A patent/JP2024114982A/ja active Pending
-
2025
- 2025-03-19 US US19/083,757 patent/US20250302910A1/en active Pending